Cargando…

Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile

The objective of this article is to describe the experience in Chile, during 2021 and 2022, with the validation of COVID-19 vaccines administered abroad and the main obstacles during the implementation of this process. This validation is given throughout South America and, in the case of Chile, it h...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos-López, Matías, Alvear-Muñoz, Francisco, Arévalo-Galdames, Felipe, Díaz-Navarrete, Vannia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Organización Panamericana de la Salud 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100993/
https://www.ncbi.nlm.nih.gov/pubmed/37066127
http://dx.doi.org/10.26633/RPSP.2023.62
_version_ 1785025411050110976
author Santos-López, Matías
Alvear-Muñoz, Francisco
Arévalo-Galdames, Felipe
Díaz-Navarrete, Vannia
author_facet Santos-López, Matías
Alvear-Muñoz, Francisco
Arévalo-Galdames, Felipe
Díaz-Navarrete, Vannia
author_sort Santos-López, Matías
collection PubMed
description The objective of this article is to describe the experience in Chile, during 2021 and 2022, with the validation of COVID-19 vaccines administered abroad and the main obstacles during the implementation of this process. This validation is given throughout South America and, in the case of Chile, it has been a successful undertaking with the validation of more than two million vaccines from different countries. Validation is a systematic process involving reviews conducted by trained professionals, which helps maintain international relations with other countries and fulfill the objectives set forth by the health authority. Despite the project’s success, it has brought to light situations such as digital gaps in the population and differences in the reporting systems and types of vaccines administered in each country. The following solutions have been proposed: a public contact center for users having difficulty with the technology; more flexible requirements for validation; and the possibility of continuing with the vaccination program in Chile, always focused on protecting the population, reducing the potential risk of disease transmission, and maintaining public health.
format Online
Article
Text
id pubmed-10100993
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Organización Panamericana de la Salud
record_format MEDLINE/PubMed
spelling pubmed-101009932023-04-14 Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile Santos-López, Matías Alvear-Muñoz, Francisco Arévalo-Galdames, Felipe Díaz-Navarrete, Vannia Rev Panam Salud Publica Temas De Actualidad The objective of this article is to describe the experience in Chile, during 2021 and 2022, with the validation of COVID-19 vaccines administered abroad and the main obstacles during the implementation of this process. This validation is given throughout South America and, in the case of Chile, it has been a successful undertaking with the validation of more than two million vaccines from different countries. Validation is a systematic process involving reviews conducted by trained professionals, which helps maintain international relations with other countries and fulfill the objectives set forth by the health authority. Despite the project’s success, it has brought to light situations such as digital gaps in the population and differences in the reporting systems and types of vaccines administered in each country. The following solutions have been proposed: a public contact center for users having difficulty with the technology; more flexible requirements for validation; and the possibility of continuing with the vaccination program in Chile, always focused on protecting the population, reducing the potential risk of disease transmission, and maintaining public health. Organización Panamericana de la Salud 2023-04-14 /pmc/articles/PMC10100993/ /pubmed/37066127 http://dx.doi.org/10.26633/RPSP.2023.62 Text en https://creativecommons.org/licenses/by-nc-nd/3.0/us/Este es un artículo de acceso abierto distribuido bajo los términos de la licencia Creative Commons Attribution-NonCommercial-NoDerivs 3.0 IGO, que permite su uso, distribución y reproducción en cualquier medio, siempre que el trabajo original se cite de la manera adecuada. No se permiten modificaciones a los artículos ni su uso comercial. Al reproducir un artículo no debe haber ningún indicio de que la OPS o el artículo avalan a una organización o un producto específico. El uso del logo de la OPS no está permitido. Esta leyenda debe conservarse, junto con la URL original del artículo. Crédito del logo y texto open access: PLoS, bajo licencia Creative Commons Attribution-Share Alike 3.0 Unported.
spellingShingle Temas De Actualidad
Santos-López, Matías
Alvear-Muñoz, Francisco
Arévalo-Galdames, Felipe
Díaz-Navarrete, Vannia
Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
title Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
title_full Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
title_fullStr Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
title_full_unstemmed Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
title_short Homologación de vacunas contra la COVID-19: experiencia y desafíos desde su implementación en Chile
title_sort homologación de vacunas contra la covid-19: experiencia y desafíos desde su implementación en chile
topic Temas De Actualidad
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100993/
https://www.ncbi.nlm.nih.gov/pubmed/37066127
http://dx.doi.org/10.26633/RPSP.2023.62
work_keys_str_mv AT santoslopezmatias homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile
AT alvearmunozfrancisco homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile
AT arevalogaldamesfelipe homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile
AT diaznavarretevannia homologaciondevacunascontralacovid19experienciaydesafiosdesdesuimplementacionenchile